BTG2
Overview
BTG2 (BTG Anti-Proliferation Factor 2) encodes an anti-proliferative protein that regulates cell cycle progression by inhibiting cyclin D1 transcription and interacting with protein arginine methyltransferases. It functions as a tumor suppressor in multiple cancer contexts. In bladder cancer, BTG2 was identified as a novel significantly mutated gene.
Alterations observed in the corpus
- Identified as one of 9 novel significantly mutated genes (SMGs) not previously reported as significantly mutated in any cancer; significantly mutated in muscle-invasive bladder carcinoma (BLCA, n=131) by MutSig 1.5 (FDR<0.1) in the TCGA bladder urothelial carcinoma study PMID:24476821
- Mutations in 30% of PCNSL cases (n=18); identified in genome-wide analysis of primary central nervous system lymphoma PMID:25991819
Cancer types (linked)
- Bladder urothelial carcinoma (BLCA): novel SMG identified by TCGA; exact mutation frequency not reported separately from the broader SMG list; part of the 32 SMGs in 131 chemotherapy-naive muscle-invasive tumors PMID:24476821
Co-occurrence and mutual exclusivity
- No specific co-occurrence patterns reported; identified in the context of the dominant chromatin-regulator mutation landscape of BLCA (76% of tumours with inactivating chromatin regulator mutations) PMID:24476821
Therapeutic relevance
- No targeted therapy data. As an anti-proliferative tumor suppressor, BTG2 loss could contribute to cell cycle deregulation in BLCA; no specific therapeutic strategy reported PMID:24476821
Open questions
- Mutation frequency and specific variant spectrum of BTG2 in BLCA not detailed in the primary publication; functional role of BTG2 loss in bladder carcinogenesis requires validation PMID:24476821
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:25991819
This page was processed by crosslinker on 2026-05-14.